Motilal Oswal's research report on Mankind Pharma
Mankind Pharma (MANKIND) delivered better-than-expected 2QFY25 performance, fueled by a strong revival in growth of the consumer business and continued growth momentum in the exports business. MANKIND continues to deliver a better growth rate than the industry in the Rx-prescription business, supported by a niche portfolio and superior execution in chronic therapies. However, this was partly offset by the pricing impact on certain brands and festival/seasonality in acute therapies.We tweak our earnings estimates (-3.7%/3.0% for FY26/FY27) factoring in: a) addition of business from the BSV acquisition, b) sustained growth prospects in exports, and c) a scale-up in the consumer healthcare business. We value the stock at 45x 12M forward earnings to arrive at our TP of INR3,140.
Outlook
We tweak our earnings estimates (-3.7%/3.0% for FY26/FY27) factoring in: a) addition of business from the BSV acquisition, b) sustained growth prospects in exports, and c) a scale-up in the consumer healthcare business. We value the stock at 45x 12M forward earnings to arrive at our TP of INR3,140.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
